Project Grant R01CA285740
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 25, 2025, with a completion date of July 31, 2030. This grant funds the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cell therapy for treating small cell lung cancer (SCLC), a disease with exceptionally poor prognosis and limited...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $136,266 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 14, 2025, through June 30, 2027. The grant funds research aimed at identifying therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. The research focuses on understanding the...
- This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $169,884 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2025 through June 30, 2027. The award funds biomedical research training and investigator-led research focused on elucidating molecular mechanisms underlying small cell lung cancer (SCLC) pathogenesis and identifying novel therapeutic targets. Specifically, the research...
- This $844,231 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to target the POU2F3 protein in small cell lung cancer. The two-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will enable Moffitt Cancer Center to conduct dual up- and downstream targeting of POU2F3, a...
- Federal Project Grant Award Summary Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, received a $166,800 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports research to develop and evaluate improved methods for treating lung adenocarcinoma, specifically targeting SMARCA4-mutant lung adenocarcinoma through combination...
- GRANT SUMMARY The National Cancer Institute awarded Weill Medical College of Cornell University a $607,849 Project Grant on August 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a five-year research initiative examining mechanisms of genetic and non-genetic resistance to KRAS (Kirsten Rat Sarcoma) inhibition in lung adenocarcinoma and colorectal cancer. The research aims to identify why patients develop resistance to newly emerged mutant-selective and pan-KRAS...
- The Albert Einstein College of Medicine has been awarded a $882,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a novel targeted drug therapy to treat small cell lung cancer (SCLC). The award will support research activities from June 1, 2024 through May 31, 2027. As a highly experienced recipient of federal research grants and contracts, the college has a track record of conducting biomedical research and...
MODULATING CYSTEINE METABOLISM TO INDUCE CELL DEATH IN SMALL CELL LUNG CANCER - SUMMARY SMALL CELL LUNG CANCER (SCLC) IS A FATAL FORM OF LUNG CANCER WHOSE DEVELOPMENT IS CLOSELY ASSOCIATED WITH TOBACCO SMOKING. PATIENTS WITH SCLC HAVE A MEDIAN OVERALL SURVIVAL OF ONLY 8-10 MONTHS AFTER INITIAL DIAGNOSIS. SCLC DEVELOPMENT IS FREQUENTLY ASSOCIATED WITH MUTATIONS IN TP53 (P53), RB, AND RELATED TUMOR SUPPRESSOR GENES THAT GOVERN TRANSIT THROUGH THE CELL CYCLE. DISRUPTION OF THESE GENES LEADS TO SMALL, RAPIDLY DIVIDING CELLS. DESPITE IDENTICAL MUTATIONS, SCLC CELLS CAN ADOPT ONE OF SEVERAL DISTINCT TRANSCRIPTIONAL/EPIGENETIC STATES, INCLUDING NEUROENDOCRINE AND NON-NEUROENDOCRINE STATES. HOW THESE CELL STATES DIFFER IS POORLY UNDERSTOOD. IT IS ALSO UNCLEAR HOW BEST TO INDUCE CELL DEATH IN DIFFERENT SCLC CELL STATES. IN THIS RESEARCH, WE FOCUS ON THE UNIQUE METABOLISM OF SCLC CELLS TO IDENTIFY NEW AND EXPLOITABLE VULNERABILITIES THAT CAN BE USED TO KILL SCLC CELLS. IN PRELIMINARY RNA SEQUENCING AND MASS SPECTROMETRY-BASED METABOLOMICS STUDIES WE FIND THAT SCLC METABOLISM IS CELL STATE-DEPENDENT. OUR RESULTS PINPOINT A CELL-STATE-SPECIFIC ROLE FOR CYSTINE/CYSTEINE (CYS) METABOLISM IN SCLC BIOLOGY. WE FIND THAT BOTH NEUROENDOCRINE AND NON-NEUROENDOCRINE SCLC CELLS REQUIRE CYS TO PROLIFERATE. IN THE ABSENCE OF CYS, NON-NEUROENDOCRINE CELLS STOP DIVIDING WHEREAS NEUROENDOCRINE CELLS DIE. INTRIGUINGLY, CELL DEATH RESPONSES ARE ALSO CELL STATE-DEPENDENT: ASCL1HIGH NEUROENDOCRINE CELLS PRIMARILY DIE FROM APOPTOSIS WHILE NEUROD1HIGH NEUROENDOCRINE CELLS DIE FROM FERROPTOSIS. THESE FINDINGS SUGGEST CELL STATE- SPECIFIC DIFFERENCES IN SCLC METABOLISM MAY REGULATE DISTINCT SENSITIVITIES TO APOPTOTIC VERSUS NON-APOPTOTIC CELL DEATH. IN THIS RESEARCH, WE WILL DETERMINE HOW CYS DEPRIVATION TRIGGERS CELL STATE-SPECIFIC LETHAL MECHANISMS IN SCLC CELLS. WE PROPOSE THREE SPECIFIC AIMS. WE WILL FIRST DETERMINE HOW DISTINCT NEUROENDOCRINE CELL STATES DICTATE THE CHOICE TO DIE BY APOPTOSIS VERSUS FERROPTOSIS, FOCUSING ON THE ROLE OF THE GCN2/ATF4 AMINO ACID SENSING PATHWAY AND POLYUNSATURATED PHOSPHOLIPID METABOLISM. NEXT, WE WILL DETERMINE HOW THE NOTCH AND THE NRF2 SIGNALING PATHWAYS GOVERN THE RESPONSES OF NEUROENDOCRINE VERSUS NON-NEUROENDOCRINE CELL STATES TO CYS DEPRIVATION. FINALLY, WE WILL DEVELOP A NOVEL CYS-DEGRADING ENZYME THERAPY THAT SELECTIVELY TARGETS SCLC CELLS TO INDUCE CELL DEATH BY RECOGNIZING SPECIFIC CELL SURFACE ANTIGENS. THESE STUDIES WILL TEST OUR CENTRAL HYPOTHESIS, WHICH IS THAT CYS METABOLISM REPRESENT A NOVEL TARGETABLE VULNERABILITY FOR SCLC. ALTOGETHER, THIS RESEARCH WILL UNVEIL NOVEL LINKS BETWEEN CELL STATE, METABOLISM, AND CELL DEATH IN SCLC. ULTIMATELY, WE AIM TO SHOW HOW TARGETING THIS METABOLIC NETWORK COULD LEAD TO NEW TREATMENTS FOR THIS DEVASTATING DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $530.8k | 6/17/25 | ||
| Not listed | $530.8k | 7/24/24 | ||
| Not listed | $530.8k | 7/24/24 |